ACRX - アセルRX・ファ―マシュ―ティカルズ （AcelRx Pharmaceuticals Inc.） アセルRX・ファ―マシュ―ティカルズACRXのチャート
ACRXの企業情報
| symbol | ACRx |
|---|---|
| 会社名 | AcelRx Pharmaceuticals Inc （アセルRX・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 AcelRx Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04 Zalviso which utilize sublingual sufentanil delivered through a non-invasive route of administration and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation anxiety reduction and pain relief for patients undergoing painful procedures in a physician''s office. It also includes ARX-02 which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer. アセルRX・ファ―マシュ―ティカルズは米国の医薬品会社。急性疼痛や突出痛用の治療薬の開発と商業化に重点を置く。候補薬には入院患者向け急性痛自己治療システム｢Zalviso｣、および救急処置室や救急病院用の中度・重度疼痛治療のスフェンタニルナノ粒子錠剤がある。本社はカリフォルニア州。 AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. AcelRx has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S., is being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. |
| 本社所在地 | 351 Galveston Drive Redwood City CA 94063 USA |
| 代表者氏名 | Adrian Adams エイドリアンアダムス |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-216-3500 |
| 設立年月日 | 38534 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 41人 |
| url | www.acelrx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/acrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -31.00100 |
| 終値（lastsale） | 2.99 |
| 時価総額（marketcap） | 181193742.86 |
| 時価総額 | 時価総額（百万ドル） 160.58980 |
| 売上高 | 売上高（百万ドル） 3.38800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 215.42480 |
| 当期純利益 | 当期純利益（百万ドル） -10.92800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AcelRx Pharmaceuticals Inc revenues decreased 80% to $1.2M. Net loss decreased 23% to $22.1M. Revenues reflect Collaboration agreement revenue decrease of 88% to $625K Contract and other decrease of 2% to $536K. Lower net loss reflects Research and development - Balancing val decrease of 45% to $6M (expense) General and Administrative - Balancing v decrease of 6% to $6.8M (expense). |
ACRXのテクニカル分析
ACRXのニュース
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday 2022/07/07 11:26:52 InvestorPlace
Source: ventdusud / Shutterstock.com We’re taking a look at the biggest pre-market stock movers for Thursday that investors need to know about! Moving stocks this morning is clinical trial data, plans for a stock split, and more. Let’s get into that news below! Pre-Market Stock Movers: 10 Top Gainers Allena Pharmaceuticals (NASDAQ: ALNA ) stock is rocketing more than 39% after announcing the rescheduling of a meeting to vote on a reverse stock split. United Maritime (NASDAQ: USEA ) shares are gaining over 32% following its public debut after a spinoff . AcelRx Pharmaceuticals (NASDAQ: ACRX ) stock is soaring more than 25% alongside heavy trading of the shares. Leafly Holdings (NASDAQ: LFLY ) shares are surging over 17% despite a lack of news this morning. Cryptyde (NASDAQ: TYDE ) stock is increasing more than 16% roughly one week after its public debut . Dave (NASDAQ: DAVE ) shares are rising about 16% in pre-market trading Thursday. Veru (NASDAQ: VERU ) stock is climbing over 12% as it continues to rally on a clinical trial udpate .
Analysts’ Recommendations to Consider: HP Inc. (NYSE:HPQ), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) 2022/07/06 23:50:35 Stock Equity
HP Inc. (HPQ) with the stream of -1.17% also noticed, India AcelRx Pharmaceuticals, Inc. (ACRX) encountered a rapid change of 3.60% in the last hour of trading session. HP Inc. … The post Analysts’ Recommendations to Consider: HP Inc. (NYSE:HPQ), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) appeared first on Stocks Equity .
Akebia Therapeutics And 20 Stocks Moving Premarket 2022/07/01 10:56:18 Benzinga
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. Fast Radius, Inc. (NASDAQ: FSRD ) rose 57.2% to $0.9900 in pre-market trading after jumping over 37% on Thursday. Fast Radius recently appointed Pat McCusker as President, Interim CFO and John Nanry as COO. Akebia Therapeutics, Inc. (NASDAQ: AKBA ) rose 33.1% to $0.4701 in pre-market trading after the company executed an agreement to terminate its vadadustat collaboration and license agreements with Otsuka Pharmaceutical. Shift Technologies, Inc. (NASDAQ: SFT ) rose 27.7% to $0.86 in pre-market trading after declining around 7% on Thursday. ECMOHO Limited (NASDAQ: MOHO ) rose 27.5% to $0.2093 in pre-market trading after dropping over 4% on Thursday. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) rose 22.8% to $0.30 in pre-market trading. OceanPal Inc. (NASDAQ: OP ) rose 15.5% to $0.55 in pre-market trading. OceanPal recently announced entry into agreement to acquire capesize dry bulk vessel.
Revelation Biosciences (REVB) Stock Soars 120% 2022/06/30 17:02:28 InvestorPlace
Little-known biotech company Revelation Biosciences (NASDAQ: REVB ) is soaring in early afternoon trading, but there does not seem to be any company news triggering the 120% rally of REVB stock. The company develops “immunologic-based therapies for the prevention and treatment of disease.” Its top drug candidate, REVTx-99b, treats allergic rhinitis (also known as hay fever) and chronic nasal congestion. REVB Stock: What Has Revelation Been Up To Back in January, Revelation disclosed that the viral load of single human cells that received the company’s coronavirus treatment prior to infection was more than 50% below cells that did not receive the treatment. The experiments involving Revelation’s drug REVTx-99 took place in a lab. “These results, along with our early clinical study results … suggest REVTx-99 creates an anti-viral state in relevant cell types and encourage us to continue our work to demonstrate the anti-viral potential for REVTx-99,” said Revelation CEO James Rolke in a statement.
When Would Be The Best Time To Buy AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Stock? 2022/06/29 19:00:00 Stocks Register
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) traded at $0.23 at last check on Wednesday, June 29, made an upward move of 5.39% on its previous day’s price. Looking at the stock we see that its previous close was $0.22 and the beta (5Y monthly) reads 0.67 with the day’s price range being $0.21 – $0.235. In terms … When Would Be The Best Time To Buy AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Stock? Read More »
Akebia Therapeutics And 20 Stocks Moving Premarket 2022/07/01 10:56:18 Benzinga
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. Fast Radius, Inc. (NASDAQ: FSRD ) rose 57.2% to $0.9900 in pre-market trading after jumping over 37% on Thursday. Fast Radius recently appointed Pat McCusker as President, Interim CFO and John Nanry as COO. Akebia Therapeutics, Inc. (NASDAQ: AKBA ) rose 33.1% to $0.4701 in pre-market trading after the company executed an agreement to terminate its vadadustat collaboration and license agreements with Otsuka Pharmaceutical. Shift Technologies, Inc. (NASDAQ: SFT ) rose 27.7% to $0.86 in pre-market trading after declining around 7% on Thursday. ECMOHO Limited (NASDAQ: MOHO ) rose 27.5% to $0.2093 in pre-market trading after dropping over 4% on Thursday. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) rose 22.8% to $0.30 in pre-market trading. OceanPal Inc. (NASDAQ: OP ) rose 15.5% to $0.55 in pre-market trading. OceanPal recently announced entry into agreement to acquire capesize dry bulk vessel.
Revelation Biosciences (REVB) Stock Soars 120% 2022/06/30 17:02:28 InvestorPlace
Little-known biotech company Revelation Biosciences (NASDAQ: REVB ) is soaring in early afternoon trading, but there does not seem to be any company news triggering the 120% rally of REVB stock. The company develops “immunologic-based therapies for the prevention and treatment of disease.” Its top drug candidate, REVTx-99b, treats allergic rhinitis (also known as hay fever) and chronic nasal congestion. REVB Stock: What Has Revelation Been Up To Back in January, Revelation disclosed that the viral load of single human cells that received the company’s coronavirus treatment prior to infection was more than 50% below cells that did not receive the treatment. The experiments involving Revelation’s drug REVTx-99 took place in a lab. “These results, along with our early clinical study results … suggest REVTx-99 creates an anti-viral state in relevant cell types and encourage us to continue our work to demonstrate the anti-viral potential for REVTx-99,” said Revelation CEO James Rolke in a statement.
When Would Be The Best Time To Buy AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Stock? 2022/06/29 19:00:00 Stocks Register
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) traded at $0.23 at last check on Wednesday, June 29, made an upward move of 5.39% on its previous day’s price. Looking at the stock we see that its previous close was $0.22 and the beta (5Y monthly) reads 0.67 with the day’s price range being $0.21 – $0.235. In terms … When Would Be The Best Time To Buy AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Stock? Read More »
AcelRx Pharmaceuticals Inc. (ACRX) Shares Have Declined -62.87% Year To Date 2022/06/28 15:00:00 Marketing Sentinel
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) has a beta value of 0.73 and has seen 1.51 million shares traded in the last trading session. The company, currently valued at $33.86M, closed the last trade at $0.21 per share which meant it gained $0.03 on the day or 15.56% during that session. The ACRX stock price is -638.1% … AcelRx Pharmaceuticals Inc. (ACRX) Shares Have Declined -62.87% Year To Date Read More »
AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Shares Are Set To Rise By 2022 2022/06/23 15:30:00 Stocks Register
AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) shares, rose in value on Wednesday, 06/22/22, with the stock price down by -0.82% to the previous day’s close as strong demand from buyers drove the stock to $0.19. Actively observing the price movement in the last trading, the stock closed the session at $0.19, falling within a range of $0.1906 … AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) Shares Are Set To Rise By 2022 Read More »
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022 2022/03/03 21:05:00 PR Newswire
HAYWARD, Calif., March 3, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Thursday, March 10, 2022. AcelRx management will host a live webcast…
AcelRx announces data on pain drug sufentanil sublingual for use in awake plastic surgery 2022/02/01 20:39:22 Seeking Alpha
AcelRx Pharmaceuticals (ACRX) announced real-world data for sufentanil sublingual tablet ((SST)) for pain management in patients undergoing awake plastic surgery showing a rapid…
Volume Buzz: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), AbbVie Inc. (NYSE:ABBV) 2021/12/14 23:41:09 Stock Equity
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) with the stream of -3.03% also noticed, India AbbVie Inc. (NYSE:ABBV) encountered a rapid change of 0.62% in the last hour of Tuesdays trading session. AcelRx The post Volume Buzz: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), AbbVie Inc. (NYSE:ABBV) appeared first on Stocks Equity .
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Position Lowered by Goldman Sachs Group Inc. 2021/12/13 09:08:42 Dakota Financial News
Goldman Sachs Group Inc. decreased its stake in shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) by 45.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 107,938 shares of the specialty pharmaceutical companys stock after selling 91,266 shares during the period. Goldman Sachs Group Inc.s holdings in []